M. Garneau

发表

Human Intestinal Transporter Database: QSAR Modeling and Virtual Profiling of Drug Uptake, Efflux and Interactions

A. Tropsha, Alexander Sedykh, D. Fourches, 2013, Pharmaceutical Research.

Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor

J. Duan, M. Garneau, P. Bonneau, 2014, Antimicrobial Agents and Chemotherapy.

Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold.

J. Duan, O. Hucke, M. Garneau, 2012, Bioorganic & medicinal chemistry letters.

A prodrug strategy for the oral delivery of a poorly soluble HCV NS5B thumb pocket 1 polymerase inhibitor using self-emulsifying drug delivery systems (SEDDS).

J. Duan, M. Garneau, Timothy A. Stammers, 2015, Bioorganic & medicinal chemistry letters.

Discovery of hepatitis C virus NS3-4A protease inhibitors with improved barrier to resistance and favorable liver distribution.

M. Garneau, P. White, Jeff O'meara, 2014, Journal of medicinal chemistry.

Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: discovery of potent succinamide inhibitors.

M. Garneau, P. White, Jeff O'meara, 2013, Bioorganic & medicinal chemistry letters.

Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-arylproline analogs.

M. Garneau, P. White, Jeff O'meara, 2013, Bioorganic & medicinal chemistry letters.

Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series.

J. Duan, M. Garneau, S. LaPlante, 2010, Bioorganic & medicinal chemistry letters.

Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A

J. Duan, M. Garneau, G. Kukolj, 2010 .

Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).

J. Duan, M. Garneau, S. LaPlante, 2012, Journal of medicinal chemistry.

Thiotetrazole alkynylacetanilides as potent and bioavailable non-nucleoside inhibitors of the HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases.

J. Duan, M. Garneau, P. Bonneau, 2007, Bioorganic & medicinal chemistry letters.

Indole 5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase with nanomolar potency in cell-based subgenomic replicons (part 2): central amino acid linker and right-hand-side SAR studies.

Martin Poirier, J. Duan, M. Garneau, 2011, Bioorganic & medicinal chemistry letters.

Multi-parameter optimization of aza-follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 2: Impact of lipophilicity on promiscuity and in vivo toxicity.

J. Duan, M. Garneau, S. LaPlante, 2015, Bioorganic & medicinal chemistry letters.

Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor

J. Duan, M. Garneau, P. White, 2012, Xenobiotica; the fate of foreign compounds in biological systems.

Sema3A Antibody BI-X Prevents Cell Permeability and Cytoskeletal Collapse in HRMECs and Increases Tip Cell Density in Mouse Oxygen-Induced Retinopathy

M. Garneau, Rachel Kroe-Barrett, N. Zippel, 2022, Translational vision science & technology.

Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase.

M. Garneau, M. Cordingley, A. Faucher, 2004, Antiviral research.

Phosphatidylinositol 4-Kinase III Beta Is Essential for Replication of Human Rhinovirus and Its Inhibition Causes a Lethal Phenotype In Vivo

O. Hucke, M. Garneau, J. Neyts, 2013, Antimicrobial Agents and Chemotherapy.

Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.

O. Hucke, M. Garneau, C. Brochu, 2013, Bioorganic & medicinal chemistry letters.

Characterization of a ULK1 Agonist

M. Garneau, 2018 .

Characterization of a ULK 1 Agonist

M. Garneau, 2018 .

Discovery of BI 207524, an indole diamide NS5B thumb pocket 1 inhibitor with improved potency for the potential treatment of chronic hepatitis C virus infection.

J. Duan, M. Garneau, P. Anderson, 2014, Journal of medicinal chemistry.

Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV.

J. Duan, M. Garneau, C. Yoakim, 2014, ACS medicinal chemistry letters.

Identification of potent and orally bioavailable nucleotide competing reverse transcriptase inhibitors: in vitro and in vivo optimization of a series of benzofurano[3,2-d]pyrimidin-2-one derived inhibitors.

J. Duan, M. Garneau, S. Morin, 2013, Bioorganic & medicinal chemistry letters.

Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease

Peter W. White, J. Duan, M. Garneau, 2010, Antimicrobial Agents and Chemotherapy.

Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.

Martin Poirier, M. Garneau, D. Lamarre, 2004, Journal of medicinal chemistry.

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: structure-activity relationships (SAR) of the C3-phenyl moiety.

J. Duan, O. Hucke, M. Garneau, 2013, Bioorganic & medicinal chemistry letters.

N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies.

J. Duan, M. Garneau, C. Brochu, 2010, Bioorganic & medicinal chemistry letters.

Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335).

M. Garneau, M. Bös, P. White, 2010, Journal of medicinal chemistry.

Assessment of CYP3A‐mediated drug–drug interaction potential for victim drugs using an in vivo rat model

J. Duan, M. Garneau, N. Rioux, 2013, Biopharmaceutics & drug disposition.

Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease

M. Garneau, R. Déziel, C. Brandt, 1996, Antimicrobial agents and chemotherapy.

HPMPC therapy of MCMV-induced retinal disease in the SCID mouse measured by electroretinography, a non-invasive technique.

F. Tremblay, M. Garneau, M. Cordingley, 2003, Antiviral research.

Cutaneously applied acyclovir acts systemically in the treatment of herpetic infection in the hairless mouse.

M. Garneau, G. Bolger, F. Liard, 1997, Antiviral Research.

777 PRECLINICAL CHARACTERIZATION OF NON-COVALENT HCV NS3/4A PROTEASE INHIBITOR BI 201335

J. Duan, M. Garneau, G. Kukolj, 2010 .

Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay.

M. Garneau, S. LaPlante, R. Coulombe, 2013, Bioorganic & medicinal chemistry letters.

Acute murine cytomegalovirus infection: a model for determining antiviral activity against CMV induced hepatitis.

M. Garneau, M. Cordingley, G. Bolger, 1999, Antiviral research.

The Liver Partition Coefficient-Corrected Inhibitory Quotient and the Pharmacokinetic-Pharmacodynamic Relationship of Directly Acting Anti-Hepatitis C Virus Agents in Humans

J. Duan, M. Garneau, G. Kukolj, 2012, Antimicrobial Agents and Chemotherapy.

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.

Araz Jakalian, Sébastien Morin, Yves Bousquet, 2014, ACS medicinal chemistry letters.

Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs.

J. Duan, M. Garneau, P. Bonneau, 2016, ACS medicinal chemistry letters.

Allosteric N-acetamide-indole-6-carboxylic acid thumb pocket 1 inhibitors of hepatitis C virus NS5B polymerase - Acylsulfonamides and acylsulfamides as carboxylic acid replacements

P. Kuhn, J. Duan, M. Garneau, 2013 .

From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons.

J. Duan, M. Garneau, J. Gillard, 2011, Bioorganic & medicinal chemistry letters.

A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo

M. Garneau, P. Beaulieu, J. Chafouleas, 1994, Nature.

Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity.

M. Garneau, C. Yoakim, N. Moss, 1996, Journal of medicinal chemistry.

Human Intestinal Transporter Database: QSAR Modeling and Virtual Profiling of Drug Uptake, Efflux and Interactions

A. Tropsha, Alexander Sedykh, D. Fourches, 2013, Pharmaceutical Research.

Quantification of Drugs in Distinctly Separated Ocular Substructures of Albino and Pigmented Rats

M. Garneau, T. Schönberger, A. Rimpelä, 2020, Pharmaceutics.

Regulation of Hepatic Insulin Sensitivity and Hepatic Steatosis by ULK1

M. Garneau, E. Abel, Quanjiang Zhang, 2018, Diabetes.

Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.

J. Duan, M. Garneau, P. Bonneau, 2005, Journal of Medicinal Chemistry.

Discovery of tetrahydroindazoles as a novel class of potent and in vivo efficacious gamma secretase modulators.

M. Garneau, S. Hobson, P. Sieger, 2018, Bioorganic & medicinal chemistry.

A strategy to reduce biliary clearance in early drug discovery.

J. Duan, M. Garneau, N. Rioux, 2013, Journal of pharmacological and toxicological methods.